This suggests that SMB can be a valuable source for the prevention and treatment of atopic dermatitis, with DS showing higher activity in inhibiting factors such as TARC (thymus and activation-regulated chemokine; CCL17), RANTES (regulated on activation, normal T-cell expressed and secreted; CCL5), MDC (macrophage-derived chemokine; CCL22), MCP-1 (monocyte chemoattractant protein-1), IL-6 (interleukin-6), and IL-8 (interleukin-8). The gene discussed is CCL22; the disease is Dravet syndrome.